Testing effectiveness (Phase 2)Study completedNCT02028988What this trial is testingEnzalutamide + External Beam Rt For ProstateWho this might be right forIntermediate Risk Prostate Cancer Dana-Farber Cancer Institute 64
Testing effectiveness (Phase 2)Study completedNCT02689427What this trial is testingEnzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast CancerWho this might be right forInvasive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7+9 more M.D. Anderson Cancer Center 24
Testing effectiveness (Phase 2)Looking for participantsNCT06236139What this trial is testingCell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forMetastatic Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8 Fred Hutchinson Cancer Center 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511What this trial is testingAn Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCWho this might be right forMetastatic Castration Resistant Prostate Cancer (mCRPC) Novartis Pharmaceuticals 7
Not applicableStudy completedNCT02669771What this trial is testingLong-Term Specified Drug Use-Results Survey for Xtandi CapsuleWho this might be right forCastration-resistant Prostate Cancer Astellas Pharma Inc 1,018
Large-scale testing (Phase 3)UnknownNCT05627752What this trial is testingDocetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC StageWho this might be right forProstate CancerCastrate Resistant Prostate Cancer Zhongnan Hospital 120
Not applicableStudy completedNCT02669147What this trial is testingDetermine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPCWho this might be right forCastration Resistant Prostate Cancer (CRPC) Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 160
Testing effectiveness (Phase 2)Study completedNCT02256111What this trial is testingEXTEND Exercise TrialWho this might be right forNon-metastatic, Hormone naïve Prostate Cancer Duke University 26
Testing effectiveness (Phase 2)Study completedNCT03899467What this trial is testingThe Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPCWho this might be right forMetastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Suzhou Kintor Pharmaceutical Inc, 61
Testing effectiveness (Phase 2)Looking for participantsNCT05726292What this trial is testingEnzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate CancerWho this might be right forProstate CancerProstate Adenocarcinoma University of Chicago 90
Testing effectiveness (Phase 2)Looking for participantsNCT06228053What this trial is testingStudy of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer Syntrix Biosystems, Inc. 53
Not applicableLooking for participantsNCT07181122What this trial is testingQuality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate CancerWho this might be right forMetastatic Hormone-Sensitive Prostate Cancer (mHSPC) Ankara Etlik City Hospital 102
Large-scale testing (Phase 3)Study completedNCT02003924What this trial is testingSafety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerWho this might be right forNonmetastatic Castration-Resistant Prostate CancerProstate CancerCancer of the Prostate Pfizer 1,401
Testing effectiveness (Phase 2)Ended earlyNCT02379390What this trial is testingCabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or EnzalutamideWho this might be right forProstate Cancer Metastatic Sanofi 8
Not applicableStudy completedNCT02813226What this trial is testingAssessment of New Molecular Imaging Strategies for Prostate CancerWho this might be right forProstate Cancer Ontario Clinical Oncology Group (OCOG) 36
Post-approval studies (Phase 4)Study completedNCT02918968What this trial is testingStudy on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate CancerWho this might be right forProstate Cancer Astellas Pharma Inc 206
Not applicableLooking for participantsNCT07672119What this trial is testingLearn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or DarolutamideWho this might be right forProstate Cancer Bayer 3,000
Testing effectiveness (Phase 2)Study completedNCT03297385What this trial is testingDynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen AblationWho this might be right forProstate CancerDNAAndrogen Receptor Abnormal The Netherlands Cancer Institute 50
Post-approval studies (Phase 4)Ended earlyNCT02441517What this trial is testingEnzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel TreatmentWho this might be right forMetastatic Castration Resistant Prostate Cancer Astellas Pharma Global Development, Inc. 4
Testing effectiveness (Phase 2)Study completedNCT01927627What this trial is testingEnzalutamide in Patients With High-risk Prostate CancerWho this might be right forAdenocarcinoma of the Prostate Case Comprehensive Cancer Center 42